-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the FDA has approved Dupilumab's 300mg single-dose pre-fill pen for all Dupixent adaptations in patients 12 years of age and older, including epithelial dermatitis, asthma and chronic nasal sinusitis with nasal dipherone (CRSwNP).
the new pre-filled pen will provide patients with a more convenient way to manage Dupixent.
Bill Sibold, vice president of Sanofi, said: "Dupixent prefill pens are developed to meet the needs of patients and provide the latest technical support, including audio-visual tips."
the 300mg pre-fill pen, which is expected to be available in the U.S. in the third quarter of 2020, features hidden needles and single-press auto-injection, as well as visual and audio feedback to help patients manage themselves. "The treatment of chronic inflammatory diseases, such as adiotic dermatitis, asthma and chronic nasal-sinusitis, is complex and burdens on patients," said George D. Yancopoulos, M.D., founder of
Regeneration.
Dupixent pre-filled pen will make it easier for patients to inject."
.